B-Temia

B-Temia defines its mission as “helping people regain their autonomy through mobility, with dignity and confidence, and thus improve their quality of life”.

With its dedicated team of engineers, technicians, manufacturing and customer service specialists, focusing on the development, the production and the commercialization of bio-robotic powered assistive devices for human mobility, the company aims at becoming the global leader in the high growth market of human augmentation.

Its proprietary technology called “DermoskeletonTM” provides the user with additional strength and mechanical assistance to the movement for the recovery, support, and increase of biomechanical functions.

In 2015, five years after its foundation, B-Temia launches “KeeogoTM”, its first medical product, that assists people who are gradually losing their autonomy in walking due to a neuro or ortho-degenerative disease such as Parkinson’s, stroke, Multiple Sclerosis, or knee/hip osteoarthritis. KeeogoTM is duly approved by Health Canada; it received its CE-Marking in December 2019; the FDA clearance for the U.S. market and the authorization to be commercialized in Taiwan in September 2020. It is currently available in Canada, in Europe, in Asia and in the United States, and is manufactured in three locations: Chongqing (China), Taiwan and Quebec City (Canada).

https://www.b-temia.com/

Founded in 2010, B-TEMIA Inc. is a developer and manufacturer of biorobotic technology in the growing market of human augmentation. Its proprietary Dermoskeleton™ technology provides improved mobility, strength and autonomy to the user, with applications in the medical, industrial and military fields.